Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 …
Q3: continued sales and earnings progress
Paris, October 24, 2025
Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91
Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit
Dupixen… [4456 chars]
Source: GlobeNewswire | Published: 2025-10-24T00:00:00Z
Credit: GlobeNewswire
